Aligos Therapeutics, Inc. (NASDAQ:ALGS) Receives $41.50 Average Price Target from Brokerages

Aligos Therapeutics, Inc. (NASDAQ:ALGS) has received a consensus rating of “Moderate Buy” from the five research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $41.50.

ALGS has been the subject of a number of research reports. Wall Street Zen downgraded Aligos Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Westpark Capital initiated coverage on Aligos Therapeutics in a research report on Thursday, March 26th. They set a “buy” rating and a $48.00 price target for the company. Jefferies Financial Group raised Aligos Therapeutics to a “strong-buy” rating in a research report on Thursday, March 26th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Aligos Therapeutics in a research report on Wednesday, March 11th. Finally, UBS Group initiated coverage on Aligos Therapeutics in a research report on Wednesday, January 7th. They set a “buy” rating and a $20.00 price target for the company.

Institutional Investors Weigh In On Aligos Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. boosted its position in shares of Aligos Therapeutics by 900.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock worth $93,000 after buying an additional 9,000 shares during the period. NorthCrest Asset Manangement LLC purchased a new stake in shares of Aligos Therapeutics in the third quarter worth about $98,000. Susquehanna International Group LLP purchased a new stake in shares of Aligos Therapeutics in the third quarter worth about $99,000. HRT Financial LP purchased a new stake in shares of Aligos Therapeutics in the fourth quarter worth about $106,000. Finally, DRW Securities LLC purchased a new stake in shares of Aligos Therapeutics in the fourth quarter worth about $111,000. Hedge funds and other institutional investors own 60.43% of the company’s stock.

More Aligos Therapeutics News

Here are the key news stories impacting Aligos Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and kept a $50.00 price target on ALGS — signaling strong analyst conviction and providing a material upside reference versus the current stock price. MarketBeat ALGS Coverage
• Positive Sentiment: The firm raised FY2026–FY2030 EPS estimates across multiple years (FY2026: -$7.23 from -$8.25; FY2027: -$3.38 from -$4.06; FY2028: -$2.68 from -$3.02; FY2029: -$2.41 from -$2.61; FY2030: -$0.84 from -$1.06), implying an improved long‑term earnings trajectory and lower expected cumulative losses. MarketBeat ALGS Coverage
• Positive Sentiment: HC Wainwright made a large upward revision to Q2 2026 (from -$2.59 to -$0.22) and materially reduced loss expectations for several future quarters — a sign their model now expects nearer‑term operational improvements or lower cash burn. MarketBeat ALGS Coverage
• Negative Sentiment: HC Wainwright cut several near‑term quarterly EPS forecasts (notably Q3 2026 from -$1.72 to -$2.64 and Q1 2027 from -$1.27 to -$1.83), signaling potential near‑term headwinds (clinical timing, higher short‑term expenses, or slower milestones) that can pressure the stock. MarketBeat ALGS Coverage
• Negative Sentiment: Smaller downward tweaks to Q4 2026 and Q3 2027 EPS show some volatility in quarterly modeling — investors should expect quarter‑to‑quarter variability and monitor upcoming clinical/data milestones or cash‑flow disclosures. MarketBeat ALGS Coverage

Aligos Therapeutics Trading Down 0.8%

Aligos Therapeutics stock opened at $6.51 on Monday. The firm has a market capitalization of $40.30 million, a P/E ratio of -0.76 and a beta of 2.62. The stock has a fifty day moving average price of $7.23 and a 200 day moving average price of $8.41. Aligos Therapeutics has a 52 week low of $4.20 and a 52 week high of $13.69.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.09) by $0.18. Aligos Therapeutics had a negative return on equity of 28.16% and a negative net margin of 1,106.72%.The firm had revenue of $0.17 million during the quarter, compared to the consensus estimate of $0.27 million. As a group, equities analysts predict that Aligos Therapeutics will post -7.41 EPS for the current year.

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.